500,000 Shares in Aardvark Therapeutics, Inc. $AARD Purchased by Braidwell LP

Key Points

• Braidwell LP purchased 500,000 shares of Aardvark Therapeutics, Inc. for about $3.76 million, now holding around 2.30% of the company.
• Analysts have mixed views on Aardvark Therapeutics, with target prices ranging from $19.00 to $40.00, and an average rating of "Buy" according to recent reports.
• Aardvark's stock price opened at $8.30, with a one-year low of $4.88 and a high of $19.58, while the company recently reported a quarterly earnings loss of $0.66 per share.

Braidwell LP bought a new position in Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 500,000 shares of the company's stock, valued at approximately $3,755,000. Braidwell LP owned about 2.30% of Aardvark Therapeutics at the end of the most recent quarter.

Separately, Walleye Capital LLC purchased a new stake in Aardvark Therapeutics in the first quarter worth approximately $88,000.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD traded up $0.11 during midday trading on Friday, reaching $8.60. The stock had a trading volume of 139,793 shares, compared to its average volume of 87,039. The stock has a 50-day moving average of $11.52 and a 200-day moving average of $10.79. Aardvark Therapeutics, Inc. has a 12-month low of $4.88 and a 12-month high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.14).

Analysts Set New Price Targets

AARD has been the topic of a number of recent research reports. Royal Bank Of Canada lowered their target price on Aardvark Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a report on Thursday, August 14th. HC Wainwright initiated coverage on shares of Aardvark Therapeutics in a report on Monday, June 30th. They set a "buy" rating and a $40.00 target price for the company. Wall Street Zen cut shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, Bank of America cut their price objective on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a "buy" rating for the company in a research report on Thursday, August 28th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Aardvark Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $32.60.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.